ClinicalTrials.gg
RecruitingNCT05791994EVASIONUpdated Apr 6, 2026

EVASION: Effect of VisuAl Stimulation on attentION

An interventional study of Visual cognitive stimulation exercises and Broadcast of a television program in Mild Cognitive Impairment, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.

Planned enrollment
108th of 139
40 · median 88
Started
2026
with 4 others
No phase
104 of 189
32 open now
Primary completion
2027-01
later than 26 of 59 live
Registered
142nd of 189
by date

Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 108th largest by planned enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2026, is one of 104 with no phase, reaches primary completion later than 26 of the 59 other live ones, and was the 142nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Cognitive Dysfunction with a site in France, or all of them as a file.
02

Study summary

The main objective is to compare changes in information processing speed after 30 days of intervention in participants with a dysexecutive mild cognitive impairment (MCI) and receiving either cognitive stimulation by adapted visual exercises (Emeraude® software) or the broadcasting of a television program without cognitive stimulation.

Secondary objectives are:

  • To compare, after 30 days of intervention, in participants with a dysexecutive MCI and receiving either cognitive stimulation by adapted visual exercises (Emeraude® software), or the broadcasting of a television program without cognitive stimulation :
  • changes in information processing speed of each subtest,
  • changes in cognitive performance,
  • changes in executive functions,
  • changes in walking performance.
  • To compare the quality of life, after 30 days of intervention, of participants with a dysexecutive MCI and receiving either cognitive stimulation by adapted visual exercises (Emeraude® software) or the broadcasting of a television program without cognitive stimulation.
  • In the "Intervention" group, to study correlations between changes in information processing speed index and the final level reached for each cognitive stimulation exercise.
Read the detailed description

Attentional abilities are among the cognitive functions that are most frequently and earliest altered during aging, particularly in the case of neurodegenerative diseases such as Alzheimer's disease. This decline can be the cause of a cognitive complaint in the patient or his relatives from the prodromal stage of the disease. This mild cognitive impairment is not sufficiently advanced to have an impact on independence and autonomy, even though recent studies have reported an early modification of walking in this population, in particular in the case of a dysexecutive MCI. The current challenge is to develop strategies to prevent cognitive decline in these patients with MCI and to avoid conversion to major neurocognitive disorders. However, while "memory workshops" are offered to patients with amnestic MCI, no strategy is clearly identified for dysexecutive MCI.

Interestingly, the integration of sensory information is modified in patients with neurodegenerative diseases, and in particular visuomotor difficulties in the early stages. Measurements of evoked potentials during visual stimulation have shown that sensory responses are preserved but cognitive responses are reduced in patients with MCI. Based on this observation, an American team recently tested the effectiveness of computer-assisted visual cognitive exercises performed regularly for 8 weeks in patients without dementia, and reported an improvement in information processing speed and walking performance. These results lead us to hypothesize that regular cognitive stimulation exercises using adapted visual exercises could improve the attentional capacities and in particular the information processing speed (=mental speed) of elderly people with a dysexecutive MCI.

A complex brain stimulation software Emeraude® has recently been developed by the Centre Régional Basse Vision in Angers from a software used for more than 30 years in people with visual impairment.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Geriatrics
  • Cognitive impairment
  • Visual stimulation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 years
  • Diagnosis of mild cognitive impairment of a dysexecutive or multidomain dysexecutive nature, according to Winblad consensus criteria
  • Presence of an informal caregiver
  • Subject gave and signed to participate in the study
  • Affiliation to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Presence of severe depressive symptoms (4-item Geriatric Depression Scale score > 2)
  • Ophthalmological or central pathology that may affect the performance of stimulation exercises
  • Regular use of psychotropic drugs that may have an impact on the performance of stimulation exercises, in the opinion of the investigator (benzodiazepines, antidepressants, neuroleptics, hypnotics)
  • Use of anticonvulsant drugs
  • Existence of a confusional syndrome
  • Participation in another simultaneous clinical trial
  • Person deprived of liberty by judicial or administrative decision
  • Person under forced psychiatric care
  • Person subject to a legal protection measure
  • Person unable to give consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Procedure: Visual cognitive stimulation exercises

  • Active comparator
    Comparator group

    Procedure: Broadcast of a television program

Interventions

  • ProcedureVisual cognitive stimulation exercises

    Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.

  • ProcedureBroadcast of a television program

    Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.

06

What researchers measure

Primary outcomes

  1. Changes in information processing speed

    Changes in information processing speed is assessed by processing speed index

    Time frame: Baseline and after 30 days of intervention

Secondary outcomes

  1. Changes in information processing speed of each subtest

    This outcome is assessed by Symbol Search end Coding scores

    Time frame: Baseline and after 30 days of intervention

  2. Changes in cognitive performance

    This outcome is assessed by ADAS-cog score

    Time frame: Baseline and after 30 days of intervention

  3. Changes in executive functions (cognitive flexibility)

    Cognitive flexibility is measured by time needed to perform the Trail-Making Test (TMT) part B minus A

    Time frame: Baseline and after 30 days of intervention

  4. Changes in executive functions (cognitive inhibition)

    Cognitive inhibition is measured by time needed to perform the interference task minus the time needed to perform the denomination task

    Time frame: Baseline and after 30 days of intervention

  5. Changes in executive functions (working memory updating)

    Working memory updating is assessed by digit span test

    Time frame: Baseline and after 30 days of intervention

  6. Changes in walking performance

    Changes in walking performance is assessed by changes in coefficient of variation of stride time

    Time frame: Baseline and after 30 days of intervention

  7. Changes in quality of life

    Quality of life is assessed by 36-Item Short Form Health Survey (SF-36)

    Time frame: Baseline and after 30 days of intervention

  8. Correlations between changes in information processing speed index and the final level reached for each cognitive stimulation exercise

    This outcome is assessed by the final level achieved for each cognitive stimulation exercise

    Time frame: After 30 days of intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

Supporting information: Study protocol

Time frame: The data will be shared after signing a negotiated data transfer agreement ( data access agreement), for the duration specified in the agreement.

Access criteria: The data will be made available via secure transfer (sharing platform approved by the university hospital: BlueFiles or Oodrive).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 6 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Mar 30, 2023
StartEst.
Jul 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05791994
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
Jul 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Marine ASFAR, MD
Contact
marine.asfar@chu-angers.fr
+33 2 41 35 47 25

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion